Financial Reports

As on December 31, 2024
bt_bb_section_bottom_section_coverage_image

Financial Summary 2024

Revenue
15,438,429 SR

Net Loss
(164,462,344) SR

Revenue

Industrial Investment, 15,438,429 SR

Profit from the activity

Medical Investment, (5,656,757) SR

Industrial Investment, 1,843,715 SR

Investment sector (12,847,399) SR

Discontinuous operations (159,115,417) SR

Assets

18.4%
Current Assets
1,437,154,051 SR
83%
Fixed Assets
1,358,057,012 SR

Liabilities and Shareholder Equity

65%
Liabilities
1,119,727,176 SR
35%
Shareholder Equity
613,019,220 SR

2024 Milestones

Increasing the company's capital by offering priority rights shares.
Completion of all legal and financial studies related to the fundamental deal with Dallah Healthcare Company.
Helping subsidiaries' companies list their shares on the financial market.

Future Plans

The company's board of directors is working hard to re-assessment the company's investment strategy following the completion of the major transaction of selling its subsidiaries through one deal (Al-Ahsa Medical Services Company and Al-Salam Medical Services Company). The company is working to update its future investment plans to ensure they align with the aspirations of its shareholders, with a focus on promoting sustainable growth and enhancing the efficiency of financial performance, to achieve the highest returns for its shareholders.

Future Expectations

The company expects to complete the substantial deal with Dallah Healthcare Company in 2025.
The company is currently studying all available opportunities as it seeks to reformulate the company's investment strategies.

Structural changes

Completion of the capital increase process worth 200 million SAR through the offering of priority rights shares.
Signing of an acquisition and subscription agreement to sell all shares in Al-Ahsa Medical Services Company and Al-Salam Medical Services Company to Dallah Healthcare Company, with all required approvals obtained. Revenues and expenses of these subsidiaries were reclassified as discontinued operations.
Invitation to shareholders to vote on the amendment of the use of proceeds from the 200 million SAR priority rights offering.
Approval by the Capital Market Authority to register Tawariyat Medical Care Company (affiliate) for direct listing on the parallel market.
Sale of part of the company’s stake in the Arab Paper Manufacturing Company (Warak).
Opening of nominations for Board of Directors membership for the new three-year term starting 07/01/2025.
Clarification regarding the non-binding agreement between Al-Salam Medical Services Company and Aramco, confirming no material financial impact on the company’s operations.
bt_bb_section_top_section_coverage_image
https://ayyan.com.sa/wp-content/uploads/2020/08/floating_image_06.png
https://ayyan.com.sa/wp-content/uploads/2020/08/floating_image_08.png

For more information

You can download 2024 Board Director Report
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Other Year Reports

https://ayyan.com.sa/wp-content/uploads/2020/08/floating_image_04.png